Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kamada ( (IL:KMDA) ) has provided an announcement.
On August 11, 2025, Kamada Ltd. announced that the FDA approved its plasma collection center in Houston, Texas, allowing it to commence commercial sales of normal source plasma. The facility, which has an annual collection capacity of approximately 50,000 liters, is expected to contribute $8 million to $10 million in annual revenue at full capacity. This approval strengthens Kamada’s position in the specialty plasma market, with the Houston center anticipated to be one of the largest in the U.S. for specialty plasma collection. Kamada plans to seek further approval from the European Medicines Agency for this site, enhancing its operational capabilities and market reach.
The most recent analyst rating on (IL:KMDA) stock is a Hold with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company focuses on products for rare and serious conditions and aims to drive growth through organic commercial activities, business development, and expanding its plasma collection operations. Kamada currently operates three plasma collection centers in Texas and is advancing its product development pipeline.
YTD Price Performance: 14.77%
Average Trading Volume: 42,149
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.43B
See more data about KMDA stock on TipRanks’ Stock Analysis page.